The company states: “Our Board of Directors has approved a program authorizing the repurchase of up to $200 million of the company’s common stock. Purchases under this program may be made in the open market, in privately negotiated transactions or otherwise. The timing and amount of any repurchases will be determined based on market conditions, our stock price and other factors. The program does not require the company to repurchase any specific number of shares of its common stock and may be modified, suspended or discontinued at any time without notice.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CORT:
- Biotech Alert: Searches spiking for these stocks today
- Corcept Therapeutics price target lowered to $28 from $34 at H.C. Wainwright
- Piper still constructive on Corcept despite patent case ‘disappointing’ outcome
- Corcept Therapeutics says court finds patents not infringed
- Corcept selloff today ‘ideal buying opportunity,’ says Canaccord